GLP-1RAs were associated with a lower risk for CRC in patients with obesity/overweight compared with insulin (HR, 0.50; 95% CI, 0.33-0.75), metformin (HR, 0.58; 95% CI, 0.38-0.89), or other antidiabetics (Figure, B). This evidence concerns the gene INS and colorectal carcinoma.